CORT241220C13000
- 0.00
- 0.000.00%
Corcept Therapeutics Newsroom
Insider Sale: See Remarks of $CORT (CORT) Sells 1,411 Shares
Corcept Shares Rise More Than 60% in Three Months: Here's Why
Trump Media Saw the Largest Increase in Short Interest in October
Corcept Therapeutics Incorporated (NASDAQ:CORT) Looks Just Right With A 30% Price Jump
Corcept Therapeutics Stock Surges 61% in 2024: A Must Buy?
Truist Financial Maintains Corcept Therapeutics(CORT.US) With Buy Rating
Truist Financial Keeps Their Buy Rating on Corcept Therapeutics (CORT)
Earnings Call: Corcept Therapeutics Reports Robust Q3 Growth, Raises Guidance
A Quick Look at Today's Ratings for Corcept Therapeutics(CORT.US), With a Forecast Between $67 to $80
Corcept Therapeutics Analyst Ratings
Corcept Therapeutics Incorporated (CORT) Q3 2024 Earnings Call Transcript Summary
Corcept Therapeutics (CORT) Tops Q3 Earnings and Revenue Estimates
Express News | Corcept Therapeutics Inc Shares Down 14.7% After the Bell Following Results, Outlook
12 Health Care Stocks Moving In Wednesday's After-Market Session
Corcept Therapeutics | 10-Q: Q3 2024 Earnings Report
Corcept Therapeutics | 8-K: CORCEPT THERAPEUTICS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS, POSITIVE RESULTS FROM PHASE 3 GRADIENT TRIAL IN PATIENTS WITH CUSHING'S SYNDROME AND PROVIDES CORPORATE UPDATE
Express News | Corcept Therapeutics Inc - 2024 Revenue Guidance Raised to $675-$700 Million
Express News | Corcept Therapeutics Q3 Cash & Investments USD 547.6 Million
Express News | Corcept Therapeutics Q3 Revenue USD 182.546 Million Vs. IBES Estimate USD 172 Million
Press Release: Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing's Syndrome and Provides Corporate Update